Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Gas Research
Published in: Medical Gas Research 1/2011

Open Access 01-12-2011 | Research

Moderately delayed post-insult treatment with normobaric hyperoxia reduces excitotoxin-induced neuronal degeneration but increases ischemia-induced brain damage

Authors: Benoit Haelewyn, Laurent Chazalviel, Olivier Nicole, Myriam Lecocq, Jean-Jacques Risso, Jacques H Abraini

Published in: Medical Gas Research | Issue 1/2011

Login to get access

Abstract

Background

The use and benefits of normobaric oxygen (NBO) in patients suffering acute ischemic stroke is still controversial.

Results

Here we show for the first time to the best of our knowledge that NBO reduces both NMDA-induced calcium influxes in vitroand NMDA-induced neuronal degeneration in vivo, but increases oxygen and glucose deprivation-induced cell injury in vitroand ischemia-induced brain damage produced by middle cerebral artery occlusion in vivo.

Conclusions

Taken together, these results indicate that NBO reduces excitotoxin-induced calcium influx and subsequent neuronal degeneration but favors ischemia-induced brain damage and neuronal death. These findings highlight the complexity of the mechanisms involved by the use of NBO in patients suffering acute ischemic stroke.
Appendix
Available only for authorised users
Literature
1.
Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999, 22: 391-397. 10.1016/S0166-2236(99)01401-0.CrossRefPubMed
2.
Lo EH, Moskowitz MA, Jacobs TP: Exciting, radical, suicidal: how brain cells die after stroke. Stroke. 2005, 36: 189-192. 10.1161/01.STR.0000153069.96296.fd.CrossRefPubMed
3.
Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP: National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008, 39: 924-928. 10.1161/STROKEAHA.107.490375.CrossRefPubMed
4.
Zauner A, Daugherty WP, Bullock MR, Warner DS: Brain oxygenation and energy metabolism: part I-biological function and pathophysiology. Neurosurgery. 2002, 51: 289-302.PubMed
5.
Heo JH, Han SW, Lee SK: Free radicals as triggers of brain edema formation after stroke. Free Radic Biol Med. 2005, 39: 51-70. 10.1016/j.freeradbiomed.2005.03.035.CrossRefPubMed
6.
Mickel HS, Vaishnav YN, Kempski O, von Lubitz D, Weiss JF, Feuerstein G: Breathing 100% oxygen after global brain ischemia in Mongolian Gerbils results in increased lipid peroxidation and increased mortality. Stroke. 1987, 18: 426-430.CrossRefPubMed
7.
Sugawara T, Chan PH: Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxid Redox Signal. 2003, 5: 597-607. 10.1089/152308603770310266.CrossRefPubMed
8.
David HN, Haelewyn B, Chazalviel L, Lecocq M, Degoulet M, Risso JJ, Abraini JH: Post-ischemic helium provides neuroprotection in rats subjected to middle cerebral artery occlusion-induced ischemia by producing hypothermia. J Cereb Blood Flow Metab. 2009, 29: 1159-1165. 10.1038/jcbfm.2009.40.CrossRefPubMed
9.
David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, Risso JJ, Lemaire M, Abraini JH: Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. Faseb J. 2008, 22: 1275-1286.CrossRefPubMed
10.
David HN, Leveille F, Chazalviel L, MacKenzie ET, Buisson A, Lemaire M, Abraini JH: Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab. 2003, 23: 1168-1173.CrossRefPubMed
11.
Haelewyn B, David HN, Rouillon C, Chazalviel L, Lecocq M, Risso JJ, Lemaire M, Abraini JH: Neuroprotection by nitrous oxide: facts and evidence. Crit Care Med. 2008, 36: 2651-2659. 10.1097/CCM.0b013e318183f646.CrossRefPubMed
12.
David HN, Haelewyn B, Risso JJ, Colloc'h N, Abraini JH: Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab. 2010, 30: 718-728. 10.1038/jcbfm.2009.275.PubMedCentralCrossRefPubMed
13.
Rose K, Goldberg MP, Choi DW: Cytotoxicity in murine cortical cell cultures. In vitro biological methods. Edited by: Tyson CA, Frazier JM. 1993, San Diego, CA: Academic Press, 46-60.CrossRef
14.
Levy DI, Sucher NJ, Lipton SA: Redox modulation of NMDA receptor-mediated toxicity in mammalian central neurons. Neurosci Lett. 1990, 110: 291-296. 10.1016/0304-3940(90)90862-4.CrossRefPubMed
15.
Sucher NJ, Wong LA, Lipton SA: Redox modulation of NMDA receptor-mediated Ca2+ flux in mammalian central neurons. Neuroreport. 1990, 1: 29-32. 10.1097/00001756-199009000-00009.CrossRefPubMed
16.
Flynn EP, Auer RN: Eubaric hyperoxemia and experimental cerebral infarction. Ann Neurol. 2002, 52: 566-572. 10.1002/ana.10322.CrossRefPubMed
17.
Henninger N, Bouley J, Nelligan JM, Sicard KM, Fisher M: Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume, and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 2007, 27: 1632-1642. 10.1038/sj.jcbfm.9600463.CrossRefPubMed
18.
Kim HY, Singhal AB, Lo EH: Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol. 2005, 57: 571-575. 10.1002/ana.20430.CrossRefPubMed
19.
Singhal AB, Dijkhuizen RM, Rosen BR, Lo EH: Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. Neurology. 2002, 58: 945-952.CrossRefPubMed
20.
Singhal AB, Wang X, Sumii T, Mori T, Lo EH: Effects of normobaric hyperoxia in a rat model of focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab. 2002, 22: 861-868.CrossRefPubMed
21.
Aronowski J, Strong R, Grotta JC: Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab. 1997, 17: 1048-1056.CrossRefPubMed
22.
Kent TA, Soukup VM, Fabian RH: Heterogeneity affecting outcome from acute stroke therapy: making reperfusion worse. Stroke. 2001, 32: 2318-2327. 10.1161/hs1001.096588.CrossRefPubMed
23.
Ronning OM, Guldvog B: Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke. 1999, 30: 2033-2037.CrossRefPubMed
24.
Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG: A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke. 2005, 36: 797-802. 10.1161/01.STR.0000158914.66827.2e.CrossRefPubMed
Metadata
Title
Moderately delayed post-insult treatment with normobaric hyperoxia reduces excitotoxin-induced neuronal degeneration but increases ischemia-induced brain damage
Authors
Benoit Haelewyn
Laurent Chazalviel
Olivier Nicole
Myriam Lecocq
Jean-Jacques Risso
Jacques H Abraini
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Medical Gas Research / Issue 1/2011
Electronic ISSN: 2045-9912
DOI
https://doi.org/10.1186/2045-9912-1-2

Other articles of this Issue 1/2011

Medical Gas Research 1/2011 Go to the issue

Research

ACS6, a Hydrogen sulfide-donating derivative of sildenafil, inhibits homocysteine-induced apoptosis by preservation of mitochondrial function

Research

Hydrogen saline offers neuroprotection by reducing oxidative stress in a focal cerebral ischemia-reperfusion rat model

Research

Isoflurane does not cause neuroapoptosis but reduces astroglial processes in young adult mice

Commentary

Hyperbaric oxygen therapy promotes neurogenesis: where do we stand?

Commentary

The pacific chapter annual meeting of the undersea & hyperbaric medical society

Commentary

Molecules, magic and forgetful fruit flies: the supernatural science of medical gas research
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits